Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3563
Nov 16 • 12:34 PM ET Dollar change-0.0256 Percentage change(-6.70%)
Nov 13, 7:45 PMTempest Therapeutics Inc reports fiscal Q3 2026 results with non-GAAP EPS $-0.21 (+73% YoY) and revenue $0, beats EPS and revenue estimates
Index
-
Market Cap
7.13M
Enterprise Value
13.49M
Income
-40.59M
Sales
0.00M
Book/sh
-0.11
Cash/sh
0.04
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4
IPO
Nov 12, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
7.92
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.34
Current Ratio
0.34
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-3.91
EPS next Y
-0.49
EPS next Q
-0.15
EPS this Y
60.35%
EPS next Y
80.48%
EPS next 5Y
58.27%
EPS past 3/5Y
46.00% 76.03%
Sales past 3/5Y
- -
EPS Y/Y TTM
69.34%
Sales Y/Y TTM
-
EPS Q/Q
72.86%
Sales Q/Q
-
Insider Own
39.64%
Insider Trans
3.01%
Inst Own
2.94%
Inst Trans
14.05%
ROA
-313.56%
ROE
-1797.61%
ROIC
-991.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-22.04%
SMA50
-46.90%
SMA200
-74.04%
Trades
Shs Outstand
16.89M
Shs Float
12.07M
52W High
9.75 -96.35%
52W Low
0.34 5.82%
Volatility
14.59% 10.70%
ATR (14)
0.05
RSI (14)
25.54
Beta
-1.53
Rel Volume
0.04
Avg Volume
2.54M
Volume
55,508
Perf Week
-1.41%
Perf Month
-42.92%
Perf Quarter
-66.70%
Perf Half Y
-80.42%
Perf YTD
-87.59%
Perf Year
-96.07%
Perf 3Y
-99.17%
Perf 5Y
-99.75%
Perf 10Y
-100.00%
Prev Close
0.38
Price
0.36
Change %
-6.70%
Consensus
Strong Buy
Avg. Price Target
$7.00
Implied Upside
+1,864.6%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 22, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$11+2,987.3%
Apr 10, 2025Downgrade
BNS logoBScotiabank
Sector Outperform → Sector Perform
Apr 10, 2025Downgrade
HH.C. Wainwright
Buy → Neutral
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+3,548.6%
Feb 08, 2024Initiated
JEF logoJJefferies
Buy$15+4,109.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Jun 23 04:56 PM
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Mar 25 05:32 PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
PresidentDr. Matthew Angel Ph.D.
CFOMs. Stephanie Horn-Warnock
Head of Business DevelopmentDr. Andrew Fang Ph.D.